OrbusNeich Medical Group Holdings (FRA:Q8T) Research & Development: €13.5 Mil (TTM As of Dec. 2025)


FRA:Q8T OrbusNeich Medical Group Holdings Ltd FRA:Q8T
96 GF Score
Price €0.37
GF Value €0.47
! 2 Warning Signs
View Full Analysis

What is OrbusNeich Medical Group Holdings Research & Development?

OrbusNeich Medical Group Holdings FRA:Q8T -3.17% 96 Research & Development is €13.5 Mil as of Dec. 2025. GuruFocus rates FRA:Q8T with a GF Score™ of 96/100 and a GF Value™ of €0.47. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OrbusNeich Medical Group Holdings's Research & Development for the six months ended in Dec. 2025 was €6.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €13.5 Mil.

OrbusNeich Medical Group Holdings  (FRA:Q8T) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OrbusNeich Medical Group Holdings Research & Development Related Terms

OrbusNeich Medical Group Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for OrbusNeich Medical Group Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrbusNeich Medical Group Holdings Research & Development Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 10.75 13.32 13.19 16.28 13.43

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.89 6.87 9.21 7.00 6.54
FRA:Q8T
96GF Score
OrbusNeich Medical Group Holdings Ltd FRA:Q8T
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OrbusNeich Medical Group Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €13.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €13.5 Mil mean?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a Research & Development of €13.5 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on OrbusNeich Medical Group Holdings and its competitors.
Is OrbusNeich Medical Group Holdings' Research & Development too high?
OrbusNeich Medical Group Holdings' current Research & Development is €13.5 Mil. Overall, OrbusNeich Medical Group Holdings has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does OrbusNeich Medical Group Holdings' Research & Development compare to ISRG and BDX?
OrbusNeich Medical Group Holdings' Research & Development of €13.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OrbusNeich Medical Group Holdings and its competitors. OrbusNeich Medical Group Holdings's current Research & Development is €13.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrbusNeich Medical Group Holdings stock overvalued right now?
OrbusNeich Medical Group Holdings (FRA:Q8T) has a current Research & Development of €13.5 Mil. The stock's GF Value™ is €0.47, compared to a current price of €0.37 — trading 22.1% below its estimated fair value. The current Research & Development is €13.5 Mil. OrbusNeich Medical Group Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OrbusNeich Medical Group Holdings (FRA:Q8T), the current Research & Development is €13.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OrbusNeich Medical Group Holdings (FRA:Q8T) Overvalued in 2026?

Based on GuruFocus' analysis, OrbusNeich Medical Group Holdings stock appears to be undervalued. The current stock price of €0.37 is trading 22.1% below its estimated GF Value™ of €0.47.

Key valuation signals for FRA:Q8T:

  • Research & Development: €13.5 Mil
  • GF Value™: €0.47 vs. price of €0.37 (22.1% below fair value)
  • GF Score™: 96/100 with 2 warning signs

No single metric tells the full story. See the FRA:Q8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OrbusNeich Medical Group Holdings Business Description

Other Exchanges 06929:Hong Kong
Address 3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich Medical Group Holdings Ltd is an investment holding company. The Company principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The group has only one operating segment. The company has presence in APAC, EMEA, Japan, United States, The PRC, and Others of which majority of revenue comes from APAC.
96GF Score

Get the complete analysis for FRA:Q8T

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price
€0.47
GF Value